NxStage Medical

NxStage Medical, Inc. is a medical technology company that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. 
Its primary product includes the NxStage System One (the System One). NxStage operates in two segments: System One and In-Center. The Company markets the System One to hospitals for treatment of acute kidney failure and fluid overload. In addition to the System One, NxStage sells a line of extracorporeal disposable products for use primarily for in-center dialysis treatments for patients with end-stage renal disease (ESRD). These products, which consist of Medisystems, include hemodialysis blood tubing sets, A.V. fistula needles and apheresis needles. The Company's blood tubing set products include the ReadySet High Performance Blood Tubing set (ReadySet), and the Streamline Airless Blood Tubing set (Streamline).

Company Growth (employees)
Type
Public
HQ
Lawrence, US
Founded
1998
Size (employees)
3,400 (est)
NxStage Medical was founded in 1998 and is headquartered in Lawrence, US

NxStage Medical Office Locations

NxStage Medical has offices in Lawrence, Lutherville-Timonium, Wakefield, Norwood and in 44 other locations
Lawrence, US (HQ)
350 Merrimack St
Orlando, US
14522 Landstar Blvd
Monroeville, US
3623 William Penn Hwy
Coconut Creek, US
7525 FL-7
Oak Brook, US
1600 16th St
Casselberry, US
d102 174 FL-436
Show all (47)

NxStage Medical Data and Metrics

NxStage Medical Financial Metrics

NxStage Medical's revenue was reported to be $96.8 m in Q1, 2017
USD

Revenue (Q1, 2017)

96.8 m

Gross profit (Q1, 2017)

41.2 m

Gross profit margin (Q1, 2017), %

43%

Net income (Q1, 2017)

(1.5 m)

EBIT (Q1, 2017)

(1.7 m)

Market capitalization (17-Aug-2017)

1.9 b

Cash (31-Mar-2017)

55.5 m
NxStage Medical's current market capitalization is $1.9 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

263.4 m301.5 m336.1 m366.4 m

Revenue growth, %

14%11%9%

Cost of goods sold

160.9 m185.6 m204.7 m214.4 m

Gross profit

102.5 m115.9 m131.5 m152 m

Gross profit Margin, %

39%38%39%41%

R&D expense

31 m

General and administrative expense

32.8 m

Operating expense total

120.3 m138.1 m146.1 m156.3 m

EBIT

(17.8 m)(22.2 m)(14.6 m)(4.3 m)

EBIT margin, %

(7%)(7%)(4%)(1%)

Interest expense

611 k863 k1.1 m1 m

Pre tax profit

(18.8 m)(23.1 m)(15.2 m)(6.2 m)

Income tax expense

(245 k)1.3 m1.1 m1.1 m

Net Income

(18.6 m)(24.3 m)(16.3 m)(7.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

74.1 m75.3 m79.5 m80.3 m86.5 m89.2 m92.2 m92 m96.8 m

Cost of goods sold

46.6 m46.7 m49.4 m49.5 m51.8 m52.7 m53.8 m52.8 m55.6 m

Gross profit

27.5 m28.6 m30.1 m30.9 m34.7 m36.5 m38.4 m39.2 m41.2 m

Gross profit Margin, %

37%38%38%38%40%41%42%43%43%

R&D expense

5.7 m6.2 m5.9 m6.6 m6.8 m7.2 m8 m8.3 m9.5 m

General and administrative expense

8.4 m8.4 m8.9 m8.6 m8.6 m8 m8.5 m7.8 m9 m

Operating expense total

14.1 m14.6 m14.8 m15.2 m15.4 m15.2 m16.5 m16.1 m18.5 m

EBIT

(6.7 m)(6.3 m)(5.6 m)(5.1 m)(1.6 m)(975 k)(1.2 m)24 k(1.7 m)

EBIT margin, %

(9%)(8%)(7%)(6%)(2%)(1%)(1%)0%(2%)

Interest expense

(195 k)(255 k)(241 k)(242 k)(312 k)(241 k)(288 k)(244 k)(203 k)

Pre tax profit

(6.9 m)(6.5 m)(5.6 m)(5.3 m)(1.7 m)(1.4 m)(1.9 m)(566 k)(2.2 m)

Income tax expense

332 k295 k307 k273 k290 k335 k348 k324 k(613 k)

Net Income

(7.2 m)(6.8 m)(5.9 m)(5.6 m)(2 m)(1.8 m)(2.2 m)(890 k)(1.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

84.1 m52.9 m59.1 m59.6 m

Accounts Receivable

20.2 m24.1 m25.2 m32.3 m

Inventories

4 m6.8 m6.3 m46.8 m

Current Assets

146.1 m129.2 m128.9 m144.9 m

PP&E

52.5 m66.6 m66.7 m61.6 m

Goodwill

41.8 m41.8 m42.7 m42.6 m

Total Assets

307 m309.7 m306.9 m317.2 m

Accounts Payable

14.6 m13.8 m10.8 m14.2 m

Total Debt

1.1 m941 k2 m1.6 m

Current Liabilities

37.6 m44.8 m42.7 m49.3 m

Total Liabilities

115.1 m

Additional Paid-in Capital

567.5 m593.1 m612.5 m631.2 m

Retained Earnings

(363.5 m)(387.5 m)(402.8 m)(407.6 m)

Total Equity

194.8 m191.6 m193.5 m202 m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.6 x1.6 x1.6 x1.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

62.1 m54.6 m51 m48.4 m51.3 m57.7 m58.5 m60.8 m55.5 m

Accounts Receivable

31.1 m27.1 m24 m26.4 m30.6 m29.1 m30.1 m30.6 m39.3 m

Inventories

43.4 m47.9 m45.3 m43.4 m42.6 m39 m41.3 m46.9 m48.5 m

Current Assets

141.1 m134.4 m126.7 m124.4 m131.5 m131.7 m135.8 m144.2 m151.2 m

PP&E

60.6 m62.3 m64.2 m64.4 m65.2 m68 m66.4 m65 m61.3 m

Goodwill

41.8 m41.8 m41.8 m41.8 m41.8 m42.7 m42.7 m42.7 m42.6 m

Total Assets

312.8 m309.2 m304.6 m301.4 m306.9 m310.9 m313.7 m319.1 m323.8 m

Accounts Payable

22.5 m22.6 m17 m12.8 m12.8 m14.1 m13.6 m14.8 m18.5 m

Current Liabilities

45.7 m46.7 m43.6 m40.9 m44.4 m43.3 m45 m48.5 m47.7 m

Additional Paid-in Capital

575.1 m580.5 m598.8 m602.6 m606.8 m615.1 m621.4 m626 m640.9 m

Retained Earnings

(375.9 m)(382.6 m)(393.1 m)(398.5 m)(400.2 m)(404.1 m)(405.8 m)(406 m)(408.8 m)

Total Equity

190.2 m186.4 m190.2 m188.5 m189.8 m195.7 m197.8 m201.2 m210.8 m

Financial Leverage

1.6 x1.7 x1.6 x1.6 x1.6 x1.6 x1.6 x1.6 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.6 m)(24.3 m)(16.3 m)(7.3 m)

Depreciation and Amortization

24.8 m27.7 m30.7 m32.6 m

Accounts Receivable

(1.1 m)(4.2 m)(1.1 m)(7.4 m)

Inventories

(20 m)(35 m)(12 m)(31.1 m)

Accounts Payable

(2.2 m)(212 k)(2.8 m)3.5 m

Cash From Operating Activities

(10.1 m)(20.3 m)10.5 m4.6 m

Purchases of PP&E

(16.2 m)(20.1 m)(11.5 m)(8.8 m)

Cash From Investing Activities

(18.5 m)(20.1 m)(10.9 m)(9.4 m)

Cash From Financing Activities

5.8 m9.5 m7.3 m5.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.2 m)(6.8 m)(5.9 m)(5.6 m)(2 m)(1.8 m)(2.2 m)(890 k)(1.5 m)

Accounts Receivable

31.1 m27.1 m24 m26.4 m30.6 m29.1 m30.1 m30.6 m39.3 m

Inventories

43.4 m47.9 m45.3 m43.4 m42.6 m39 m41.3 m46.9 m48.5 m

Accounts Payable

22.5 m22.6 m17 m12.8 m12.8 m14.1 m13.6 m14.8 m18.5 m
USDY, 2017

Revenue/Employee

28.5 k

Financial Leverage

1.5 x

NxStage Medical Market Value History

NxStage Medical Job Categories

NxStage Medical Median Salaries

Source: 27 public H-1B filings from NxStage Medical

Traffic Overview of NxStage Medical

NxStage Medical Online and Social Media Presence

NxStage Medical Company Life and Culture

You may also be interested in